# A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

> **NCT05542264** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 19 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SEP-363856
- **DRUG:** Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)

## Key facts

- **NCT ID:** NCT05542264
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-15
- **Primary completion:** 2024-02-12
- **Final completion:** 2024-02-12
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05542264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05542264, "A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05542264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*